Are peptides legal? Approved drugs, compounding, and 'research use only' in 2026

There is no single answer, because three different legal categories get called 'peptides': FDA-approved drugs, compounded prescriptions, and chemicals sold for laboratory use only. A committee vote in July 2026 moved several well-known compounds between those categories.

Published September 14, 2026

This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.

Three legal categories, one word

1. FDA-approved peptide drugs

These went through the approval process: an application, clinical trials, agency review, and labelling that states what the product is for. Semaglutide, tirzepatide and tesamorelin are in this group, each approved for specific indications. Legality here is simple: they are prescription medicines, prescribed and dispensed like any other.

2. Compounded peptides

Compounding is the preparation of a medication by a pharmacy for an individual patient. Under section 503A of the federal food and drug law, a pharmacy may compound using bulk drug substances that meet defined conditions, including appearing on FDA's list of substances that may be used. FDA also maintains a category for nominated substances it has identified as presenting significant safety risks in compounding. A compounded peptide is a lawful prescription product when it comes from this pathway. It is not an approved drug, and it was not the product studied in any registration trial.

3. Research-use-only chemicals

The third category is the one that generates the questions. Vials are sold labelled for laboratory research and not for human use. The seller is not offering a medicine, and no agency has evaluated what is in the vial. Our vendor pages document this market and carry that warning on every listing.

What actually happened in July 2026

FDA announced in the Federal Register on April 16, 2026 that its Pharmacy Compounding Advisory Committee would meet on July 23 and 24, 2026 to consider bulk drug substances nominated for inclusion on the section 503A list, and opened a public docket for comment.

At that meeting the committee voted, narrowly, to recommend several peptides for the list. BPC-157, KPV and TB-500 were recommended by a vote of eight in favour to six against with one abstention, and MOTS-cby seven to five with two abstentions. Semax and epitalon were also recommended. The votes went against FDA staff's written position, and they are advisory: the agency decides what goes on the list.

Three distinctions are worth holding onto, because coverage of the vote blurred all of them:

• A recommendation to permit compounding is not FDA approval of a drug.
• An advisory committee vote is not an agency decision.
• Eligibility for compounding still means a prescription from a licensed prescriber and preparation by a licensed pharmacy, not over-the-counter availability.

Our BPC-157 profile carries the current status with the date it was last reviewed, and the news feed tracks regulatory documents as they publish.

How enforcement actually works

FDA's most visible tool in this market is the warning letter, published in a public database. The typical letter does not say "this molecule is illegal"; it says the firm is marketing an unapproved new drug, or a misbranded one, usually by pointing at the company's own website copy, testimonials, or social media claims about treating a condition. That is why research-chemical sellers write the way they do: the claims, not the chemistry, are what create the violation.

Beyond letters, the picture has been harder. Sellers in this market have faced criminal exposure, and the practical pressure has often come from payment processors and banks rather than regulators: a vendor that loses card processing stops trading regardless of what any agency does. The largest research-peptide seller announced a voluntary closure of all operations in March 2026. Our vendor index records which sellers are still operating and which have closed.

Why the answer depends on the compound

Two compounds can be chemically similar and legally unalike. Semaglutide is an approved drug. Retatrutide is an investigational compound in trials, not approved and not on a compounding list, so no lawful prescription pathway exists for it in the United States. BPC-157 sits in a third position: recommended for compounding by an advisory committee, awaiting an agency decision, and simultaneously sold as a research chemical. A blanket statement about "peptide legality" cannot be right about all three at once, which is why every compound page here carries its own status block instead.

Sport, work, and other rulebooks

Legal status for the general public is not the only rulebook. The World Anti-Doping Agency prohibits broad classes of peptides in tested sport, including growth hormone secretagogues and various peptide hormones, and revises the list each year. Military and some employment testing regimes have their own rules. A compound can be lawfully prescribed and still end an athletic career.

What this means in practice

• If a compound is approved, it is a prescription medicine, with everything that implies.
• If it is compounding-eligible, the lawful route runs through a prescriber and a licensed pharmacy.
• If it is neither, then what is being sold is a chemical labelled not for human use, and no one has checked what is in it.
• Status changes. The date on a status block matters as much as the status itself.

Frequently asked questions